Allogene, Overland plot speedy Asia play for off-the-shelf CAR-T with $117M joint venture
David Chang got a good look at what it takes to bring CAR-T therapy to China and Asia markets when he and Arie Belldegrun struck a deal with Fosun Pharma to form a joint venture around its pioneering lymphoma treatment — which would come to be known as Yescarta — in 2017, just after submitting a BLA to the FDA.
With Allogene, the duo’s high profile startup aimed at delivering off-the-shelf CAR-T, he’s doing the same.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.